kezar life sciences pipeline

Sunday, October 23, 2022 Edit

Kezar Life Sciences Inc. August 11 2022 at 401 PM EDT.

Biotech Bay Biospace

Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune.

. Find the latest Kezar Life Sciences Inc. Kezar Life Sciences pipeline Source. Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.

September 1 2022 at 700 AM EDT. Kezars pipeline consists of three investigational compounds. Its product pipeline include KZR-616 KZR-261.

The Investor Relations website contains information about Kezar Life Sciences Incs business for stockholders potential investors and financial analysts. KZR stock quote history news and other vital information to help you with your stock trading and investing. KZR shares are soaring Tuesday following a positive clinical readout.

Kezar has a market capitalization of 25441 million on a stock price of 544 which is slightly below the midpoint of the 52-week range of 218 to 979. In addition Kezar is reporting an unaudited cash position of approximately 307 million including cash cash equivalents and marketable securities as of June 30 2022. Kezar Life Sciences hopes for zetomipzomib to become a catch-all drug for inflammatory disease may have been stunted earlier in the year but new phase 2 data suggest.

Complete Kezar Life Sciences Inc. Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update. Kezar Life Sciences corporate presentation Kezar has reported phase 1 data for KZR-616 in LN PM and DM and is currently.

Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Kezar Life Sciences. Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders.

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. Kezar Life Sciences hopes for zetomipzomib to become a catch-all drug for inflammatory disease may have been stunted earlier in the year but new phase 2 data suggest the therapy is. Stock information by Barrons.

View real-time KZR stock price and news along with industry-best analysis.

Zielbio